个人信息
Personal Information
联系方式
Contact Information
个人简介
Personal Profile
周爱萍,女,中国医学科学院肿瘤医院内科主任医师,博士生导师 一、 教育经历 1996.9- 2001.7 中国协和医科大学肿瘤学专业 硕博连读研究生 医学博士学位 1988.9-1993.7 北京医科大学 临床医学系 医学学士学位 二、 工作和任职经历 2013.9- 中国医学科学院肿瘤医院内科 主任医师 2005.9- 2013.8 中国医学科学院肿瘤医院内科 副主任医师 2001.9- 2005.9 中国医学科学院肿瘤医院内科 主治医师 1999.9- 2002.2 协和医院 内科进修 1993.9~1996.7 中国医学科学院肿瘤医院 内科 住院医师 三、工作特长 自1993年开始从事肿瘤内科工作,擅长结直肠癌、胃癌、食管癌、肝胆胰等消化道肿瘤和肾癌、膀胱癌等泌尿肿瘤的化疗、生物靶向及免疫治疗。有丰富的抗癌新药临床研究经验。担任《CSCO结直肠癌诊治指南》共同执笔人、《CSCO肾癌诊治指南》、《CSCO胃癌诊治指南》、《CSCO尿路上皮癌诊治指南》专家组成员。 四、学术兼职 中国临床肿瘤学会(CSCO)理事, 中国临床肿瘤学会(CSCO)尿路上皮癌专业委员会副主任委员,中国临床肿瘤学会(CSCO)结直肠癌/胃癌/智慧医疗专业委员会常务委员,中国临床肿瘤学会(CSCO)肾癌专业委员会委员兼秘书,中国医药教育协会腹部肿瘤结直肠癌分会副主任委员,中国老年学会老年肿瘤专业委员会副干事长、消化道肿瘤分会副主任委员,中国研究型医院精准医学与肿瘤MDT专业委员会副主任委员,中国医疗保健国际交流促进会消化道肿瘤MDT分委会副主任委员,中国医疗保健国际交流促进会结直肠癌肝转移治疗专业委员会/神经内分泌肿瘤专业委员会常务委员,中国抗癌协会胃癌专业委员会委员,中国抗癌协会抗癌药物专业委员会委员,中华医学会胰腺癌专业委员会委员,《中华肝胆外科杂志》编委,《中华临床医师杂志》编委,《中国继续教育杂志》编委,《肝癌电子杂志》编委,《中国新药杂志》,通讯编委《中华肿瘤杂志》审稿人。
团队简介
Team Profile
周爱萍导师团队主要从事消化系统肿瘤、泌尿系统肿瘤的基础与临床研究。目前,团队拥有主任医师5人,副主任医师1人,其中博士研究生导师3人。 课题组自成立以来,发扬 “尊科学济人道”的协和精神,学术研究把握肿瘤学理论前沿,在消化系统及泌尿系统肿瘤领域深入专研,不断创新。 学术研究方面:近年来,课题组近5年先后承担了中国医学科学院临床与转化医学研究专项(2023-12至2025-11):ctDNA 指导下TKI 联合PD-1 单抗用于标准治疗失败的晚期pMMR/MSS 结直肠癌的随机对照临床研究;中国医学科学院肿瘤医院重点学科基金项目(2022):菌群移植联合免疫检查点抑制剂与TKI治疗晚期结直肠癌的II期研究;国家自然科学基金(2022-01至2025-12):LncRNA DLGAP1-AS2/FAM3D/GM3调控轴介导食管鳞癌化疗耐药的机制研究;国家自然科学基金重点项目(2020-01至2024-12):食管有丝分裂灾难关键调控分子的作用机制及靶向抑制研究;国家重点研发项目(2021-12至2024-12):食管癌变动态演进机制及个体化精准诊疗体系构建研究;中国医学科学院医学与健康科技创新工程:环境因素引起的癌症的分子机理与靶标的发现(2019) 协同子课题;国家重大新药创制(2018-01至2020-12):1类抗癌新药曲沙他滨的临床研发和产业化研究。近五年科研总经费约335万元,以(共同)第一作者或(共同)通讯作者发表SCI/EI论文及核心期刊约40余篇。 学术兼职方面:现任中国临床肿瘤学会(CSCO)理事, 中国临床肿瘤学会(CSCO)尿路上皮癌专业委员会副主任委员,中国临床肿瘤学会(CSCO)结直肠癌/胃癌/智慧医疗专业委员会常务委员,中国临床肿瘤学会(CSCO)肾癌专业委员会委员兼秘书,中国医药教育协会腹部肿瘤结直肠癌分会副主任委员,中国老年学会老年肿瘤专业委员会副干事长、消化道肿瘤分会副主任委员,中国研究型医院精准医学与肿瘤MDT专业委员会副主任委员,中国医疗保健国际交流促进会消化道肿瘤MDT分委会副主任委员,中国医疗保健国际交流促进会结直肠癌肝转移治疗专业委员会/神经内分泌肿瘤专业委员会常务委员,中国抗癌协会胃癌专业委员会委员,中国抗癌协会抗癌药物专业委员会委员,中华医学会胰腺癌专业委员会委员,《中华肝胆外科杂志》编委,《中华临床医师杂志》编委,《中国继续教育杂志》编委,《肝癌电子杂志》编委,《中国新药杂志》,通讯编委《中华肿瘤杂志》审稿人。 学生培养方面:迄今为止,课题组已培养硕士7名,在读硕士2人,在读博士2人。 课题组在周爱萍老师的带领下,学术领域不断探索,临床能力不断精进。我们期待你的加入,共同学习,共同进步!
硕士研究生 2 名,博士研究生 2 名
# | 项目名称 | 起止日期 | 金额 | 项目类型 | 本人角色 |
---|---|---|---|---|---|
1 | LncRNA DLGAP1-AS2/FAM3D/GM3调控轴介导食管鳞癌化疗耐药的研究机制 | 2021-08-01 —— | 55.0 | 主持在研的国家或省部级科研项目 | 主持者 |
2 | 食管癌有丝分裂灾难关键调控分子的作用机制及靶向抑制研究 | 2020-01-31 —— | 297.0 | 参与在研的国家或省部级科研项目 | 参与者 |
3 | 食管癌变动态演进机制及个体化精准诊疗体系构建研究 | 2021-12 —— 2024-12 | 450 | 参与在研的国家或省部级科研项目 | 骨干参与 |
# | 论文题目 | 期刊名称 | 发表年份 | 论文署名 |
---|---|---|---|---|
1 | Serum concentration of CD137 and tumor infiltration by M1 macrophages predict the response to sintilimab plus bevacizumab biosimilar in advanced hepatocellular carcinoma patients | Clinical Cancer Research | 2022-06-17 | 周爱萍 |
2 | Open-label, multicenter, phase 2 study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma | Clinical Cancer Research | 2022-06-17 | 周爱萍 |
3 | 治疗相关高血压与血管内皮生长因子受体酪氨酸激酶抑制剂治疗转移性肾细胞癌疗效的关系 | 中华肿瘤杂志 | 2022-06-17 | 周爱萍 |
4 | Famitinib in metastatic renal cell carcinoma: a single center study | Chinese Medical Journal (English) | 2022-06-17 | 周爱萍 |
5 | NGS-based oncogenic mutations analysis in advanced colorectal cancer patients improves targeted therapy prediction | Pathology Research and Practice | 2022-06-17 | 周爱萍 |
6 | Encouraging Pathological Complete Response Rate from Neoadjuvant Chemotherapy with Albumin-Bound Paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Esophageal Squamous Carcinoma: Preliminary Outcome of a Retrospective Study | Cancer Management and Research | 2022-06-17 | 周爱萍 |
7 | RECIST 1.1, Choi and mChoi criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with Regorafenib and anti-PD-1 antibody | European Journal of Radiology | 2022-06-17 | 周爱萍 |
8 | Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cel lCarcinoma Treated by Targeted Therapy | Chinese Medical Journal (English) | 2022-06-17 | 周爱萍 |
9 | 抗血管生成酪氨酸激酶抑制剂治疗转移性肾细胞癌的手足皮肤反应与疗效的关系 | 中华医学杂志 | 2022-06-17 | 周爱萍 |
10 | 多西紫杉醇与替吉奥联合铂类治疗晚期胃癌的II期临床研究 | 中华医学杂志 | 2022-06-17 | 周爱萍 |
11 | Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey | HPB (Oxford) | 2022-06-17 | 周爱萍 |
12 | Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial | Frontiers Oncology | 2022-06-17 | 周爱萍 |
13 | Outcome of chemotherapy with or without targeted agents in metastatic colorectal cancer patients with deficient DNA mismatch repair: A single center, cohort study | Asia-Pacific Journal of Clinical Oncology | 2022-06-17 | 周爱萍 |
14 | Comparison of 627 patients with right- and left-sided colon cancer in China: Differences in clinicopathology, recurrence, and survival | Chronic Diseases and Translational Medicine | 2022-06-17 | 周爱萍 |
15 | Changes in expression of multiple checkpoint molecules and infiltration of tumor immune cells after neoadjuvant chemotherapy in gastric cancer | Journal of Cancer | 2022-06-17 | 周爱萍 |
16 | Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study) | Hepatology International | 2022-06-17 | 周爱萍 |
17 | Comparison of S-1 Plus Oxaliplatin (SOX) and Capecitabine Plus Oxaliplatin (XELOX) as Adjuvant Chemotherapies for Stage II and III Gastric Cancer After D2 Resection: A Single-Center Retrospective Study | Asia-Pacific Journal of Clinical Oncology | 2022-06-17 | 周爱萍 |
18 | Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial | Cancer Chemotherapy and Pharmacology | 2022-06-17 | 周爱萍 |
19 | 西妥昔单抗联合化疗一线治疗KRAS/RAS野生型转移性结直肠癌的疗效及预后因素分析 | 癌症进展 | 2022-06-17 | 周爱萍 |
20 | A study on the association between hyperlipidemia and hypothyroidism and the response to TKIs in metastatic renal cell carcinoma | Asia-Pacific Journal of Clinical Oncology | 2022-06-17 | 周爱萍 |
21 | Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial | Oncologist | 2022-06-17 | 周爱萍 |
22 | Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study | Cancer Research and Treatment | 2022-06-17 | 周爱萍 |
23 | Body mass index and age are additional prognostic factors in patients with metastatic renal cellcarcinoma treated with tyrosine kinase inhibitors | Urologic Oncology | 2022-06-17 | 周爱萍 |
24 | Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib | Cancer Chemotherapy and Pharmacology | 2022-06-17 | 周爱萍 |
25 | 替西罗莫司治疗转移性肾细胞癌初探 | 癌症进展 | 2022-06-17 | 周爱萍 |
26 | Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis | Hepatology | 2022-06-17 | 周爱萍 |
27 | 索拉非尼治疗转移性肾癌的临床研究 | 中华泌尿杂志 | 2022-06-17 | 周爱萍 |
28 | High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma | Future Oncology | 2022-06-17 | 周爱萍 |
29 | Nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule (S-1) as first-line treatment for advanced biliary tract adenocarcinoma: a phase 2 clinical trial | Hepatobiliary Surgery and Nutrition | 2022-06-17 | 周爱萍 |
30 | Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements | Liver Cancer | 2022-12 | 周爱萍 |
31 | Phenotypical screening on metastatic PRCC-TFE3 fusion translocation renal cell carcinoma organoids reveals potential therapeutic agents | Clin Transl Oncol | 2022-12 | 周爱萍 |
32 | Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma | Front Oncol | 2023-12 | 周爱萍 |
33 | Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial: A randomized clinical trial of neoadjuvant therapy for ESCC | BMC Med | 2023-12 | 周爱萍 |
34 | Exploration of the immunogenetic landscape of hyperprogressive disease after combined immunotherapy in cancer patients | iScience | 2023-12 | 周爱萍 |
35 | Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial | BMC Cancer | 2023-12 | 周爱萍 |
36 | Abnormal generation of IL-17A represses tumor infiltration of stem-like exhausted CD8 T cells to demote the antitumor immunity | BMC Med | 2023-12 | 周爱萍 |
37 | Modulation of gut microbiota: a novel approach to enhancing the effects of immune checkpoint inhibitors | Ther Adv Med Oncol | 2023-12 | 周爱萍 |
38 | Neutrophil extracellular traps in relationship to efficacy of systemic therapy for metastatic renal cell carcinoma | Cancer Med | 2023-12 | 周爱萍 |
39 | Efficacy and Safety of Disitamab Vedotin in Patients with Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials | J Clin Oncol | 2024-06 | 周爱萍 |
40 | Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial | Gastric Cancer | 2024-06 | 周爱萍 |
41 | A phase I trial of autologous RAK cell immunotherapy in metastatic renal cell carcinoma | Cancer Immunol Immunother | 2024-06 | 周爱萍 |
42 | Serum IgA as a Prognostic Beacon: Anticipating Systemic Therapy Efficacy in Metastatic Clear Cell Renal Cell Carcinoma | Ann Surg Oncol | 2024-06 | 周爱萍 |
43 | A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma | Eur J Cancer | 2024-06 | 周爱萍 |
无
无